Joint Clinical Trials Office
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis (AD) and Inadequate Response to Dupilumab (SWITCH-UP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025
Pilot of an Integrated Treatment for Comorbid PTSD and Chronic Pain
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 16, 2025
Assessment of attitudes towards PSA screening and decision aids
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 16, 2025
Gene Therapy for Alpha 1-Antitrypsin Deficiency
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 16, 2025
A012301- LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 22, 2025
Experiences of individuals who have participated in Crystal Meth Anonymous: a qualitative study
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 31, 2025
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 8, 2026
BIO89-100-131: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 8, 2026